VACV-encoded IFN inhibitors are secreted and intracellularly expressed factors that were lost stepwise during in vitro attenuation. (A) Flt3-L pDC were infected with VACV, MVA, and two intermediate passages, CVA152 (152) and CVA386 (386), at an MOI of 1. Controls were left untreated or stimulated with CpG 2216 (CpG; 10 μg/ml). At 24 h after infection, supernatant was analyzed for IFN-α (left panel) and IFN-β (right panel) by an ELISA method. (B) Flt3-L pDC (1 × 106) were infected with VACV, CVA152 (152), and CVA386 (386) at an MOI of 1 (left panel) or at an MOI of 10 (right panel) alone or in combination with MVA (MOI of 1). Uninfected cells served as a control. At 24 h after infection, supernatant was analyzed for IFN-α (left panel) and IFN-β (right panel) by an ELISA method. (C) Supernatants of untreated (SN −), VACV-infected (SN VACV), CVA152-infected (SN 152), and CVA386-infected (SN 386) cells were generated by infection of 1 × 106 Flt3-L pDC for 2 h at an MOI of 1. The supernatants were then discarded, and cells were washed extensively and incubated for 22 h. Freshly generated Flt3-L pDC were incubated with these supernatants for 3 h and subsequently infected with MVA (MOI of 1) for 21 h. At 24 h after treatment, supernatant was analyzed for IFN-α (left panel) and IFN-β (right panel) by an ELISA method. The data shown are representative of two or three independent experiments. Error bars indicate standard deviations from triplicate ELISA measurements. *, P = <0.05 and ≥0.01; **, P = <0.01 and ≥0.001; ***, P = <0.001 (unpaired two-tailed t test).